12月，石药集团、百济神州、百花村医药等一批药企已“换帅”

制药网2025-12-23

2025年以来，为应对行业变革，加速战略转型、减缓业绩压力与提升治理效率，国内医药行业高管变动一直频繁。如在近期，石药集团、百济神州、百花村医药等一批药企就已纷纷宣布“换帅”。12月20日，新疆百花村医药审议通过了《关于聘任公司2026年度轮值总经理的议案》，董事会同意聘任黄辉先生为公司2026年度轮值总经理，任期一年。公开资料显示，黄辉先生具备丰富的医药研发与管理经验，现任公司董事、南京华威医药...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2593741940?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-23 15:17","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2593741940","market":"hk","top_or_hot":-1,"title":"12月，石药集团、百济神州、百花村医药等一批药企已“换帅”","media":"制药网","content":"<div>\n<p>2025年以来，为应对行业变革，加速战略转型、减缓业绩压力与提升治理效率，国内医药行业高管变动一直频繁。如在近期，石药集团、百济神州、百花村医药等一批药企就已纷纷宣布“换帅”。12月20日，新疆百花村医药审议通过了《关于聘任公司2026年度轮值总经理的议案》，董事会同意聘任黄辉先生为公司2026年度轮值总经理，任期一年。公开资料显示，黄辉先生具备丰富的医药研发与管理经验，现任公司董事、南京华威医药...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223152053a46dc612&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>12月，石药集团、百济神州、百花村医药等一批药企已“换帅”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n12月，石药集团、百济神州、百花村医药等一批药企已“换帅”\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-23 15:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223152053a46dc612&s=b><strong>制药网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2025年以来，为应对行业变革，加速战略转型、减缓业绩压力与提升治理效率，国内医药行业高管变动一直频繁。如在近期，石药集团、百济神州、百花村医药等一批药企就已纷纷宣布“换帅”。12月20日，新疆百花村医药审议通过了《关于聘任公司2026年度轮值总经理的议案》，董事会同意聘任黄辉先生为公司2026年度轮值总经理，任期一年。公开资料显示，黄辉先生具备丰富的医药研发与管理经验，现任公司董事、南京华威医药...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223152053a46dc612&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ08YR35.GBP","symbol_name":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223152053a46dc612&s=b","article_id":"2593741940","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223152053a46dc612&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2593741940","pubTimestamp":1766474250,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"如在近期，石药集团、百济神州、百花村医药等一批药企就已纷纷宣布“换帅”。12月19日，石药集团公告宣布执行董事蔡磊接任董事会副主席、首席执行官。12月12日，药明巨诺发布公告，宣布一系列核心管理层及董事会架构调整。除了上述企业，在12月以来，恒瑞医药、康恩贝、南新制药、振东制药等也已发布过高管变动公告。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1583":"高瓴概念","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU0359201612.USD":"贝莱德中国基金A2","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","09939":"开拓药业-B","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1500":"做空集合股","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","01276":"恒瑞医药","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","06160":"百济神州","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","BK1588":"回港中概股","BK1191":"制药","BK1161":"生物科技","LU0140636845.USD":"施罗德大中华区股票A Acc","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1515":"抗疫概念","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","BK1574":"生物医药B类股","01093":"石药集团","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC"},"translate_title":"In December, a number of pharmaceutical companies such as CSPC, BeiGene, and Baihuacun Pharmaceutical have \"changed coaches\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09939":1.5,"06160":1.5,"01276":0.9,"01093":1.5},"content_text":"2025年以来，为应对行业变革，加速战略转型、减缓业绩压力与提升治理效率，国内医药行业高管变动一直频繁。如在近期，石药集团、百济神州、百花村医药等一批药企就已纷纷宣布“换帅”。12月20日，新疆百花村医药审议通过了《关于聘任公司2026年度轮值总经理的议案》，董事会同意聘任黄辉先生为公司2026年度轮值总经理，任期一年。公开资料显示，黄辉先生具备丰富的医药研发与管理经验，现任公司董事、南京华威医药科技集团有限公司董事长等职务，曾领导完成80余项新药仿制药研发及注册申报工作，承担多项国家级、省级科技项目。12月19日，石药集团公告宣布执行董事蔡磊接任董事会副主席、首席执行官。业内认为，蔡磊的走马上任，将推动集团在\"研发-生产-销售-资本运作\"全链条形成协同效应，为创新成果落地搭建更高效的转化通道。据了解，蔡磊是创始人蔡东晨之子，已在石药集团深耕积淀十余年。自2014年加入集团后，一路从附属公司总经理逐步晋升至执行总裁，历任营销运营中心及多个事业部副总裁，如今同时执掌美国研发事业部与医药产品销售事业部，负责海外研发与销售核心业务。12月19日，百济神州连发公告，宣布公司核心管理团队迎来关键变动——全球研发负责人汪来博士正式出任公司总裁，同时继续兼任全球研发负责人一职。公开资料显示，汪来博士自 2011 年公司成立初期便加入百济神州团队，历经 14 年深耕，从基层研发岗位逐步成长为全球研发负责人。其中，自 2021 年 4 月起，汪来博士便已开始执掌百济神州全球研发体系，带领团队推进多款创新药的全球临床试验与上市申报。12月12日，药明巨诺发布公告，宣布一系列核心管理层及董事会架构调整。其中，田丰将于2025年12月29日起正式出任公司行政总裁及执行董事；刘诚博士则自2025年12月12日起出任董事会主席一职。公告披露，此次接棒行政总裁一职的田丰，在生物制药行业拥有超二十年经验，在商业化、市场营销、企业运营及战略管理领域具备全面的能力。此外，还曾服务于上海罗氏制药、辉瑞制药、恒瑞医药、金赛药业等企业。除了上述企业，在12月以来，恒瑞医药、康恩贝、南新制药、振东制药等也已发布过高管变动公告。从整体来看，这些变动主要以核心管理岗换任、引入国际化人才、家族接班为主。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593741940","isCrawlerRequest":true}